MEDtalks
Senaste MEDtalk
EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan
/ Johanne Skovgaard Schovsbo
TP53 Mutations as a Predictive Biomarker in High-Risk Breast Cancer
/ Mari Eskild Rasmussen
EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma
/ Sigrun Thorsteinsdottir
AI-Based Extraction of Retrospective Pathology Data for Breast Cancer Research
/ Agnar Martin Bjørnstad
ASCO 2026: No Survival Benefit With Thoracic Radiotherapy in SCLC
/ Bjørn Henning Grønberg
Triplet Chemotherapy in HER2-Positive Gastroesophageal Cancer
/ Nour Al Houda Ayoub
Higher Lenalidomide Dosing Safe in Renal Impairment
/ Frida Bugge Askeland
Questionnaire for Late Effects After Immunotherapy
/ Debbie Maria Madsen
Breastfeeding During Ustekinumab Treatment in Inflammatory Bowel Disease Is Low Risk
/ Christina Lykke Balmer
























